Erasca, Inc.
NASDAQ:ERASBiotechnology
Healthcare
$13.76 -0.14%
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
52W Low $1.21High $24.28
Volume 8.94M
Average 6.79M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$131.41M
FY 2025 · Annual
Net Income
-$124.55M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 829K | 2.64M | 3.73M | 0 | 3.11M |
| Gross Profit | (829K) | (2.64M) | (3.73M) | 0 | (3.11M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 73.92M | 112.46M | 103.82M | 115.36M | 92.85M |
| Selling, General & Admin | 22.62M | 32.99M | 37.7M | 41.73M | 38.55M |
| Operating Expenses | 124.05M | 244.81M | 137.79M | 179.59M | 128.3M |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| EBITDA | (121.94M) | (240.16M) | (121.31M) | (153.28M) | (121.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (124.88M) | (247.45M) | (141.53M) | (179.59M) | (131.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 190K | 4.9M | 16.71M | 20.09M | 16.61M |
| Interest Expense | 0 | 201.36M | 0 | 0 | 0 |
| Other Income / Expenses | 2.12M | 4.65M | 16.48M | 17.94M | 6.86M |
| Income Before Tax | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| EPS (Diluted) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| 119.1M | 122.02M | 150.18M | 233.82M | 283.53M | |
| 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
ERAS Earnings Waterfall · TTM
NASDAQ:ERAS · Revenue to Net Income
Key Ratios
EPS$-0.99
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-18.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$307.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.99, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Oct 16, 2026 | |
| 8-K | Current report | Aug 24, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does ERAS generate?
Erasca, Inc. (ERAS) reported $0.00 of revenue in fiscal 2025.
Is ERAS profitable?
Erasca, Inc. (ERAS) reported -$124.55M of net income.
Continue the stock analysis
Jump to another research area for this company.